Ixazomib citrate is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anti-cancer agent that is used for treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate obtains higher pharmacokinetics, efficacy, and anticancer activity.
Isazomib is a proteasome inhibitor suitable for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma to receive at least one prior treatment.
Recommended starting dose of 4 mg orally on days 1,8, and 15 of the 28-day course; the dose should be at least one hour before or at least 2 hours after the food is taken.
Isazomib induces apoptosis of multiple myeloma cell lines in vitro. Isazomib showed in vitro cytotoxicity to myeloma cells from patients who had relapsed after a variety of previous treatments, including bortezomib, lenalidomide, and dexamethasone. The combination of isazomib and lenalidomide showed a synergistic cytotoxic effect in multiple myeloma cell lines. In vivo, isazomib showed anti-tumor activity in a mouse multiple myeloma tumor xenograft model.
The most common adverse reactions (≥ 20%) were Diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, Vomit, and back pain.
